For most of modern medicine's history, the only advice for a serious food allergy was avoidance and an epinephrine injector. Two approaches have changed that. Oral immunotherapy feeds the allergen in gradually escalating doses until the body stops reacting to it. The antibody drug omalizumab, approved in February 2024 for reducing allergic reactions from accidental food exposure, intercepts the immune signal that drives the reaction in the first place.

In July, JAMA Pediatrics published a randomized trial that put them head to head in people allergic to several foods at once. The headline result favoured the drug. The reason it did is more instructive than the result.

From the Lab to the Ledger

An allergic reaction to food begins with IgE antibodies that have mistakenly learned to recognize a food protein. They sit on the surface of mast cells and basophils, and when the food protein arrives and binds them, those cells release histamine and other mediators in a rush. That release is what produces hives, swelling, and in severe cases anaphylaxis.

The two treatments attack opposite ends of that chain. Omalizumab is a monoclonal antibody that binds free IgE before it can attach to mast cells, lowering the amount available to trigger a reaction regardless of which food is involved. That is why one drug covers all of a person's allergies at once. Oral immunotherapy works further back, retraining the immune response to the specific food through repeated controlled exposure, which can produce lasting tolerance but has to be done food by food.

The trial, the second stage of a study called OUtMATCH, enrolled 117 participants aged 1 to 55 at ten US academic centres, all allergic to peanut plus at least two of milk, egg, wheat, cashew, hazelnut or walnut. The median age was 7. Everyone received 16 weeks of open-label omalizumab first. Then one group continued the drug while taking placebo immunotherapy, and the other switched to placebo injections while escalating real multiallergen immunotherapy toward 1000 mg of protein per food.

Bio-Pipeline Ledger

Omalizumab for food allergy: FDA approved in February 2024 for reducing allergic reactions from accidental exposure to one or more foods. Validated, given by injection, and it reduces reaction severity rather than curing the allergy.

Multiallergen oral immunotherapy: effective in those who can tolerate it, performed at specialist centres, and not an approved product in this multi-food form. Available as a clinical protocol rather than a licensed treatment.

Single-food peanut oral immunotherapy: one approved product exists in this category. Commercially available, narrower in scope than the multiallergen approach.

Epinephrine auto-injectors: entirely validated, essential, and unchanged by any of this. Nothing here replaces carrying one.

Combining omalizumab with oral immunotherapy: the premise of the trial's first stage and an active research question, with the optimal sequence and duration still undefined.

The Clinical Reality Check

In the intention-to-treat analysis, 36 percent of the omalizumab group reached the target of tolerating at least 4044 mg of all three foods, against 19 percent on immunotherapy. That looks decisive until you read the completion figures. Eighty-eight percent of the omalizumab group finished the study; 51 percent of the immunotherapy group did. Among those who completed, the difference largely disappeared.

The reason people left is the heart of the matter. Thirty-one percent of the immunotherapy group had a serious adverse event, against none in the omalizumab group. Thirty-seven percent needed epinephrine, against 7 percent. Twenty-two percent stopped because of side effects, against none. Oral immunotherapy works by deliberately giving someone the food they are allergic to, and the trial is a precise measurement of what that costs.

So the honest conclusion is not that one treatment beats the other. It is that they have different risk profiles for the same goal, and the study's authors describe both as viable. Omalizumab is easier to tolerate and protects against accidental exposure across all of a person's allergies, but it works only while it is being given and does not retrain the immune system. Immunotherapy can build genuine tolerance to a specific food, and a substantial minority cannot get through it.

The limitations deserve weight. This was a smaller trial than planned, 117 rather than the 128 needed for full statistical power. Participants had multiple allergies and low starting thresholds, which makes them a harder group than someone allergic to one food. Treatment ran about a year, and nothing here speaks to what happens after stopping.

For a family weighing this, the useful questions for an allergist are concrete. Which foods matter most in daily life, and would protecting against accidental exposure be enough, or is the goal eating the food freely. How tolerable has immunotherapy been for similar patients at that particular centre. And either way, the epinephrine injector stays in the bag.